Clin2
NCT07223229Possibly a fitRecruiting

Testing EI-001 for vitiligo that hasn't improved with other treatments

Non-segmental Vitiligo

Part of Skin clinical trials.

This study tests a new drug called EI-001 for people with non-segmental vitiligo (a type where white patches appear on both sides of the body). It is for those whose vitiligo has not gotten better with standard treatments like creams or light therapy, or who cannot use those treatments.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
45 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You must be 18 to 65 years old.
  • You must have non-segmental vitiligo for at least 3 months that has not improved with creams, light therapy, or pills (or you cannot use these treatments).
  • The white patches on your face must cover at least 0.5% of your face, and total patches on your body must be between 5% and 60% of your skin.
  • You must stop using all other vitiligo treatments during the study.
  • If you have not had the shingles vaccine, you must be willing to get it before starting the study drug.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07431177Recruiting· Phase 2
Study of an investigational drug for non-segmental vitiligo

This study tests an investigational drug (GIA632) in people with non-segmental vitiligo. It aims to see if different doses can safely and effectively restore color to white patches.

Birmingham, Alabama
NCT07251595Recruiting· Phase 2
Testing a pill and gel for vitiligo

This trial tests two forms of a drug (SHR0302) for non-segmental vitiligo. One is a pill, the other a gel. The goal is to see if they can repigment the skin with fewer side effects.

Jinan, Shandong
NCT07667569Not yet recruiting· Phase 2
A study of ACT-777991 for adults with non-segmental vitiligo

This trial tests a new oral medication called ACT-777991 to see if it is safe and can help repigment skin in adults with non-segmental vitiligo (the most common type that affects both sides of the body). Participants must have at least a certain amount of pigment loss on the face and total body, and agree not to use other vitiligo treatments during the study.

NCT07047612Recruiting· Phase 2/Phase 3
A study of ICP-332 for people with non-segmental vitiligo

This trial tests an investigational drug called ICP-332 for vitiligo that isn't limited to one area (non-segmental). It aims to see if the drug can help restore skin color. The study is for both adults and teenagers who have had vitiligo for at least 3 months with a certain amount of skin affected.

Wuhu, Anhui
NCT07172347Recruiting· Phase 2
VC005 tablets for non-segmental vitiligo

This trial tests an oral tablet called VC005 to see if it can help treat non-segmental vitiligo. It may be an option for adults with vitiligo patches that are not limited to one area of the body.

Beijing, Beijng
NCT06511739Recruiting· Phase 2
SYHX1901 tablet for non-segmental vitiligo

This study tests an oral tablet called SYHX1901 for people with non-segmental vitiligo. It aims to see if the pill is safe and effective at bringing back skin color.

Shijiazhuang

Hear when a new Non-segmental Vitiligo trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.